NCT06790966Phase 3Terminated

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Study sponsor: PDS Biotechnology Corp. · PDSB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-08-25Actual
Enrollment · participants12Actual
Source updated2026-09-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 252 participants (planned). After: 12 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Feb 2029. After: 25 Aug 2026.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Overall Survival (OS). After: Measure: Overall Survival (OS) Measure: Progression-Free Survival (PFS).

Planned enrollment decreased by 99 participants

Before: 351 participants (planned). After: 252 participants (planned).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview